Bionik Laboratories Corp. · OTC:BNKL
Bionik Laboratories — Investor Presentation (June 2017)
23 slides from Bionik Laboratories's investor presentation, Jun 14, 2017
Slide 1: Bionik Laboratories Investor Presentation June 2017
1 BIONIK LABORATORIES Investor Presentation June 2017 www.bioniklabs.com OTCQX: BNKL @ BionikLab # MobilityForLife
Slide 2: Safe Harbor Statement
2 SAFE HARBOR STATEMENT www.bioniklabs.com WE DO NOT MAKE ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AS TO THE ACCURACY OR COMPLETENESS OF THE INFORMATION PROVIDED IN THIS DOCUMENT. WE RESERVE THE RIGHT TO AMEND, REPLACE AND/OR SUPPLEMENT THIS DOCUMENT AT ANY TIME AND UNDERTAKE NO OBLIGA
Slide 3: Bionik: Overview – Significant Growth Potential
3 BIONIK: OVERVIEW – SIGNIFICANT GROWTH POTENTIAL www.bioniklabs.com • Founded in 2011 in Toronto, Canada by Michal Prywata • Two technology platforms – Rehabilitative and Assistive Robotics • Acquired MIT spinoff to expand product portfolio • Industry leading FDA cleared rehabilitative products in
Slide 4: Management Team
www.bioniklabs.com 4 Over 25 years of executive management experience with proven track record of building public and private technology companies. Former CFO and joint Interim CEO of Sanofi Canada, CFO of Intellivax, Gennum TSX:GNM (n/k/a Semtech NASDAQ:SMTC), Just Energy (NYSE/TSX:JE); and Founder
Slide 5: Board and Advisors
www.bioniklabs.com 5 Key Advisors BOARD AND ADVISORS Board of Directors • Dr. Robert Hariri • Independent Director • Chairman, Founder, Chief Scientific Officer, and former Chief Executive Officer of Celgene Cellular Therapeutics; Board member of Myos Corporation and Provista Diagnostics • Marc Math
Slide 6: Addressing Major Healthcare Needs with Robots
6 ADDRESSING MAJOR HEALTHCARE NEEDS WITH ROBOTS There is a rapidly growing need for quality of life solutions for the millions of mobility challenged people, while reducing the financial burden to the society. Our goal is to be the market leader in evidence based rehabilitative and assistive robotic
Slide 7: Unaddressed Growing Impaired Mobility Market
7 UNADDRESSED GROWING IMPAIRED MOBILITY MARKET Roughly 50.5 MILLION people in the US have a mobility issue Extrapolated, that is over 1 BILLION globally These numbers are growing at pandemic rates as the population ages www.bioniklabs.com * https://www.census.gov/newsroom/releases/archives/miscellan
Slide 8: Stroke Epidemic: Our Major Entry Point
www.bioniklabs.com 8 STROKE EPIDEMIC: OUR MAJOR ENTRY POINT Source: Global and regional burden of stroke during 1990 – 2010: findings from the Global Burden of Disease Study 2010; 18 January 2014, Volume 383, No. 9913 Global stroke incidence per 100,000 people* Key Challenges • Stroke is the # 1 c a
Slide 9: In-Market Robots Tackling Stroke Epidemic
www.bioniklabs.com 9 IN - MARKET ROBOTS TACKLING STROKE EPIDEMIC • Designed to rehabilitate stroke patients with upper body neurological limitations • Interactive technology that continuously adapts and challenges the patient's ability • Allows the clinician to efficiently deliver personalized inten
Slide 10: Bionik Robots Improving Health Outcomes
www.bioniklabs.com 10 BIONIK ROBOTS IMPROVING HEALTH OUTCOMES Bionik Robots Conventional • Focuses on habitual movement - repetition of a few functional motor skills. • Treatment protocols are non - reproducible • Difficult to quantify true recovery • Low intensity - 25 to 45 movements per session •
Slide 11: The Bionik Advantage: A Proven Effect on Brain Plasticity
11 THE BIONIK ADVANTAGE: A PROVEN EFFECT ON BRAIN PLASTICITY InMotion technology assists the healthcare provider to: • Treat based on neuro science principles, not only functional movements • Deliver progressive “assist - as - needed” individualized treatment plans • Precisely reproduc e and measure
Slide 12: Clinically & Economically Proven - Years of Research
12 CLINICALLY & ECONOMICALLY PROVEN - 15 YEARS OF RESEARCH Clinical Validation Economic Validation • Proven to improve health outcomes • Over 200 published papers reviewing Bionik’s products • Over 1,000 patients studied in clinical trials at prestigious academic and clinical sites • Demonstrated cl
Slide 13: Robotic Therapy Recommendation Based on Bionik's Data
13 ROBOTIC THERAPY RECOMMENDATION BASED ON BIONIK’S DATA • Referencing Bionik’s cli n ica l trial s , AHA's Str o ke Division assigned highest recommendation level for r obo t a ssiste d t h er a py f o r upp er extremity m o t o r re habili tat ion of moderate to severe str o ke p at i ent s • VA s
Slide 14: Bionik Exclusively Selected for World's Largest Robotic Study
14 BIONIK EXCLUSIVELY SELECTED FOR WORLD’S LARGEST ROBOTIC STUDY • Land m a rk UK st ud y: World’s la rgest st ud y c ondu cte d w i t h r obo t i c s f o r re habili tat ion • Funded by the research arm of the National Health Service (NHS), the largest and oldest single - payer healthcare system in
Slide 15: Robots in Development Tackling Stroke Epidemic
www.bioniklabs.com 15 ROBOTS IN DEVELOPMENT TACKLING STROKE EPIDEMIC • Exoskeletal robotic system using the same design principles • Designed in close collaboration with the Newman Laboratory for Biomechanics and Human Rehabilitation • Currently available in multiple clinics for research in the U.S.
Slide 16: Assistive Technology to Enter Personal Robotics Market
16 ASSISTIVE TECHNOLOGY TO ENTER PERSONAL ROBOTICS MARKET • Exoskeleton designed for paraplegia • Planned launch first in Asia • Huge unmet medical need in China due to lack of therapists • Highest strength exoskeleton for paralysis • Lightweight intuitive exoskeleton designed to work for both parap
Slide 17: Significant Opportunity from B2B to B2C
17 SIGNIFICANT OPPORTUNITY FROM B2B TO B2C Rehab Robotics Assistive Robotics CLINICAL: Addressable Market estimated at $1B+ per year • With average selling price of $100k per robot • In Market • Clinical robots are point of entry for the home market HOME: Addressable Market estimated at $4B+ per yea
Slide 18: Product Roadmap
www.bioniklabs.com 18 PRODUCT ROADMAP PRODUCT DEVELOPMENT PRE - CLINICAL CLINICAL IN MARKET MILESTONE InMotion ARM In Market InMotion HAND In Market InMotion WRIST In Market; Updated product Q4 ’17 InMotion AHW V2 Commercial Launch Q3 ’17 ARKE Lower Body Exoskeleton Launch ARKE 2.5 in Asia InMotion
Slide 19: Growth Strategy
19 18 MONTH GROWTH STRATEGY 1. Offer clinically proven products from hospital to home ▪ Deploy our new commercial version upper body robots ▪ Expand clinical robot offering into lower extremity ▪ Extend clinical robot offering into home 2. Increase clinical install - base ▪ Target high volume inpati
Slide 20: High Growth Revenue Positioning: Snowball Effect
20 HIGH GROWTH REVENUE POSITIONING: SNOWBALL EFFECT B2B to B2C 5% cash pay patients 20 patients per month @ $4,500 per patient = $1M annually per clinical installation • 99% of stroke patients are discharged from Acute Care hospitals to Post Acute Care (PAC) settings • Just 100 “high volume” clinics
Slide 21: Financial Snapshot
21 FINANCIAL SNAPSHOT STOCK TICKER SYMBOL OTCQX: BNKL Market Capitalization as of June 9 , 2017 $ 2 8 . 1 M Shares Outstanding* 96. 8 M Warrants at exercise price of $1.40 16.4 M Warrants at exercise price of $0.80 1.2 M Amount received in grants to date $4 M *Includes 47,909,336 Exchangeable Shares
Slide 22: Summary
22 SUMMARY • Proprietary robotics product line in market focused on stroke rehabilitation and assistive technology solutions from hospital to home • Proven clinical evidence differentiates product portfolio and puts Bionik in a leading position for reimbursement • High growth revenue potential: snow
Slide 23: www.bioniklabs.com Headquarters Bay Street, Office N105 Toronto, ON M5G 2C9 Canada Investor Relations Counsel
www.bioniklabs.com 23 Headquarters 483 Bay Street, Office N105 Toronto, ON M5G 2C9 Canada Investor Relations Counsel Amato and Partners, LLC admin@amatoandpartners.com PR Contact matt@fischtankpr.com BIONIK LABORATORIES
Bionik Laboratories — Investor Presentation (June 2017) on 6ix